NCT01365585View on ClinicalTrials.gov

Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension

CompletedOBSERVATIONAL
Enrollment

227

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

sildenafil citrate

Sildenafil citrate, 20mg oral tablets, taken at least three times daily

Trial Locations (2)

7

Mater Misericordiae Hospital, Dublin

30625

Medizinische Hochschule Hannover, Hanover

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT01365585 - Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension | Biotech Hunter | Biotech Hunter